New drug shows promise for liver disease in early trial

NCT ID NCT05569759

Completed Disease control Sponsor: Kezar Life Sciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called zetomipzomib in 24 adults with autoimmune hepatitis, a condition where the immune system attacks the liver. Participants received either the drug or a placebo along with their usual treatment for 24 weeks, with an option to continue the drug for another 24 weeks. The goal was to see if the drug could improve liver health and reduce the need for steroids, while monitoring for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE HEPATITIS

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
California Pacific Medical Center

San Francisco, California, 94109, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Indiana University

Indianapolis, Indiana, 46202, United States
Keck School of Medicine of USC

Los Angeles, California, 90033, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic Arizona

Phoenix, Arizona, 85054, United States
Mayo Clinic Florida

Jacksonville, Florida, 32224, United States
New York University Langone Health/Grossman School of Medicine

New York, New York, 10016, United States
Northwell Health Center for Liver Disease and Transplantation

Manhasset, New York, 11030, United States
Northwestern University

Chicago, Illinois, 60611, United States
Ochsner Clinic Foundation

New Orleans, Louisiana, 70121, United States
Rush University

Chicago, Illinois, 60612, United States
Stanford Medicine

Redwood City, California, 94063, United States
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of California, Los Angeles

Los Angeles, California, 90095, United States
University of California, San Francisco

San Francisco, California, 94132, United States
University of Colorado

Aurora, Colorado, 80045, United States
University of Miami

Miami, Florida, 33136, United States
University of Michigan Medical Center

Ann Arbor, Michigan, 48109, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Virginia Commonwealth University

Richmond, Virginia, 23298, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Yale University

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.